Ocugen, Inc.
StreetZero Signal 59
About Ocugen, Inc.
Ocugen, Inc. (Nasdaq: OCGN) is a pioneering biotechnology leader in gene therapies for blindness diseases. The company develops a breakthrough modifier gene therapy platform with potential to address significant unmet medical needs in retinal diseases. It also pursues novel biologic therapies, regenerative medicine cell therapies, and an inhaled mucosal vaccine platform. Ocugen is headquartered in Malvern, PA and is publicly traded.
LATEST FUNDINGRule 144
$498K
Announced 2026-10-09
IN THE NEWS
- 🔗 Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock | Ocugen, Inc.
- 🔗 Ocugen - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 Ocugen merger agreement with Carisma terminated due to funding shortfall
- 🔗 Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Ocugen, Inc.
- 🔗 Ocugen Inc (OCGN) Stock Price: Oct 9 Close $0.9555 | Gotrade
EMPLOYEES—
FOUNDED—
HQMalvern, PA, United States
Industry
Public Equity (NASDAQ)
Tags
BiotechnologyGene TherapyPublicOphthalmology
Investors
Key highlights
- Closed $22.5M registered direct offering of common stock led by RTW Investments.
- Raised $130M via convertible senior notes to extend runway into 2028.
- Terminated merger agreement with Carisma Therapeutics due to funding shortfall.
- Publicly traded on NASDAQ under ticker OCGN with focus on modifier gene therapy for retinal diseases.
Ask StreetZero about Ocugen, Inc.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account